Table 4.
Univariate and multivariate analysis of variables associated with serum rituximab levels at month-3.
| Variables | Patients with serum rituximab level < 2µg/mL at month-3 (n = 38) | Patients with serum rituximab level > 2µg/mL at month-3 (n = 30) | Univariate P-value | Multivariate P-value |
|---|---|---|---|---|
| Characteristics at baseline | ||||
| Age (years) | 57.5 [44.0–67.5] | 60.5 [50.5–68.0] | 0.3 | |
| Gender (Female/Male)* | 14/24 | 5/25 | 0.1 | 0.3 |
| Weight (kg) | 76.3 [66.6-83.6] | 77.0 [67.9-86.0] | 1 | |
| UP (g/d)* | 7.0 [4.9–10.1] | 5.5 [3.9–7.1] | 0.07 | 0.2 |
| Serum creatinine (µmol/L)* | 119 [83–138] | 137 [90–183] | 0.1 | 0.3 |
| Serum albumin (g/L)* | 20.2 [14.1–24.6] | 26.6 [22.0–31.7] | 0.001 | 0.005 |
| CD19+ count (cell/µL) | 208.0 [138.0–280.0] | 142.5 [77.2–215.5] | 0.2 | |
| Etiology | 0.2 | |||
| Anti-PLA2R1-associated pMN | 35 (92.%) | 27 (90%) | ||
| Anti-THSD7A-associated pMN | 0 (0%) | 2 (7%) | ||
| Double negative patients | 3 (8%) | 1 (3%) | ||
| Anti-PLA2R1 Ab titer (RU/mL)* | 184 [71–489] | 89 [20–173] | 0.01 | 0.5 |
*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.
Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; UP, 24-hour urinary protein excretion.